Jyong Biotech (NASDAQ:MENS) Stock Price Down 19.3% - Here's What Happened

Key Points

• Jyong Biotech (NASDAQ:MENS) shares plunged 19.3% in mid-day trading to about $18.01–$18.07 from a $22.39 close, with ~151,391 shares traded — down 44% from average volume.
• Market sentiment is negative: Weiss Ratings reiterated a "sell (e+)" and MarketBeat shows the stock's average analyst rating is Sell.
• The stock is trading far below technical levels, with a 50-day simple moving average of $40.78, indicating a steep downtrend versus the current price.

Jyong Biotech Ltd. (NASDAQ:MENS - Get Free Report)'s stock price was down 19.3% during mid-day trading on Tuesday . The stock traded as low as $18.01 and last traded at $18.07. Approximately 151,391 shares changed hands during mid-day trading, a decline of 44% from the average daily volume of 269,087 shares. The stock had previously closed at $22.39.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a "sell (e+)" rating on shares of Jyong Biotech in a report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has an average rating of "Sell".

Jyong Biotech Price Performance

The firm's 50-day simple moving average is $40.78.

Hedge Funds Weigh In On Jyong Biotech

An institutional investor recently bought a new position in Jyong Biotech stock. BNP Paribas Financial Markets purchased a new stake in shares of Jyong Biotech Ltd. (NASDAQ:MENS - Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 1,698 shares of the company's stock, valued at approximately $67,000.

Jyong Biotech Company Profile

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers' health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.